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Markers for the identification of late breast cancer
recurrence
Ivana Sestak* and Jack Cuzick
Abstract
Postmenopausal women with early breast cancer are at an ongoing risk of relapse, even after successful surgery
and treatment of the primary tumor. The treatment of breast cancer has changed in the past few years because of
the discovery of prognostic and predictive biomarkers that allow individualized breast cancer treatment. However,
it is still not clear how to identify women that are at high risk of a late recurrence. Clinical parameters are good
prognostic markers for early recurrence, but only nodal status and, to a lesser extent, tumor size have proven to be
strong prognostic markers for late recurrence. Multi-gene signatures have become widely used for the prediction of
overall recurrence risk and tailoring administration of adjuvant chemotherapy, but only a few have been shown to
be prognostic for late (distant) relapse. There is a need to accurately identify women who may benefit from extended
endocrine therapy but also those who may be spared any additional treatment. Recent results from large clinical trials
have shown that the research is going in the right direction, and these results might help to optimize extended
endocrine therapy for patients with early breast cancer. However, further research is needed to select individual
biomarkers or multi-gene signatures that offer identification of late recurrence specifically and thus justify routine
use of these tests in the clinical setting.
Introduction
Breast cancer is the most common cancer in women,
and over 1.6 million cases are diagnosed annually [1]. It
is a highly heterogeneous disease with respect to clinical
and molecular characteristics. Both adjuvant endocrine
therapy and chemotherapy, after initial surgery, have
proven to be highly effective methods to reduce the risk
of disease recurrence, preventing both local and distant
metastasis [2] and reducing mortality. Despite the proven
benefits of adjuvant endocrine therapy in women with
hormone receptor positive breast cancer, relapses still
occur even after initial treatment with endocrine therapy
for 5 years. Adjuvant chemotherapy has also proven to be
effective in reducing the risk of recurrence within the first
5 years after diagnosis [2], but little is known about its
effect on long-term outcome.
For women with HR-negative disease, the risk of
recurrence is confined mostly to the first 5 years after
diagnosis and relapse rates fall rapidly thereafter [3,4].
However, women with HR-positive tumors remain at
risk for late recurrences, and the annual rate is in excess
of 2% for at least 15 years, even after 5 years of tam-
oxifen therapy [5]. The ATLAS (Adjuvant Tamoxifen:
Longer Against Shorter) and aTTom (Adjuvant Tamoxifen:
To Offer More?) trials have reported their findings, and
results show that extended tamoxifen therapy (5 additional
years) in women with early-stage breast cancer reduces the
risk of late recurrences [6]. Similar findings were observed
for aromatase inhibitors, which have been shown to reduce
the risk of late relapse if treatment was extended beyond
the initial 5 years [7,8]. However, there is a need to identify
those women at high risk of recurrence and who will bene-
fit most from these extended therapies. Thus, the benefits
of extended treatment must be weighed against potential
side effects of prolonged therapy for each individual pa-
tient. In this article, we will review the evidence for the use
of clinicopathological factors, individual biomarkers, and
multi-gene/molecular scores for the prediction of late
recurrence, especially distant recurrence.
Clinicopathological parameters
Tumor size, stage, and nodal involvement are routinely
used to estimate the likelihood of breast cancer recurrence
and are relevant for both estrogen receptor (ER)-positive
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and -negative cancer. These clinical parameters are useful
for predicting recurrence in the first 5 years after diagnosis
[9]. Distant recurrence has been associated with large
tumor size, poorly differentiated disease, and nodal in-
volvement [10], and these factors are believed to be corre-
lated also with late metastasis. However, only a few studies
have investigated the utility of these clinical factors in this
setting. The Netherlands Cancer Institute has studied 252
breast cancer patients with clinical data, long-term follow-
up, and treatment details [11] and found that, of the clin-
ical parameters, only nodal involvement was a significant
prognostic factor for late metastasis. In the large transla-
tional Arimidex, Tamioxiden Alone or in Combination
(transATAC) trial, we confirmed the role of nodal status
but also found tumor size to be an independent prognostic
factor for early and late distant recurrence, whereas grade
was predictive only in the first 5 years after diagnosis
(Table 1) [9]. These two findings are in agreement with
previously reported results that nodal involvement is the
dominant feature predicting disease-specific outcome [4].
Clinicopathological factors still have different values for the
identification of women at high risk of late recurrence, and
better discrimination is desirable. Many women with node-
positive disease receive chemotherapy, but some may be
over-treated and may be at a sufficiently low risk of recur-
rence 5 years after diagnosis. This raises the question of
the duration of endocrine treatment, and it is not yet clear
which women will benefit most from extended therapy.
Cancer-related genes
The identification of markers for the prediction of breast
cancer has been widely investigated, specifically for
the identification of biomarkers for early breast cancer
diagnosis. The evaluation of ER, progesterone receptor
(PgR), Ki67, and human epidermal growth factor (HER2)
is common in clinical practice for prognostic purposes
and treatment decisions. However, laboratory variability
in Ki67 scoring is well known and therefore this bio-
marker is not ideal for clinical decision making [12].
Other markers, such as B-cell lymphoma 2, androgen re-
ceptor, epidermal growth factor, phosphatase and tensin
homolog, and PIK3CA, have been investigated for their
prognostic value in breast cancer. Tumors with muta-
tions in PIK3CA have been shown to be associated with
lower recurrence and mortality rates in the late time
period [13,14]. Liu and colleagues [15] analyzed predic-
tors of late relapse in early-stage ER-positive breast can-
cer, in which differences in the primary tumor tissue in
patients with distant relapses occurring early (less than
3 years) versus late (after 7 years) have been compared.
A set of genes was identified that were prognostic specif-
ically for early relapse (CALM1, CALM2, CALM3, SRC,
CDK1, and MAPK1), but they also identified genes that
appear to predict late relapse (ESR1, ESR2, EGFR, BCL2,
and AR). High expression levels of BCL2 have also been
shown to be a good predictor of late breast cancer recur-
rence in a subset of 73 patients with primary breast
Table 1 Individual clinical and immunohistochemical markers for the prediction of early versus late recurrence
in transATAC
0-5 years 5-10 years
(number of all recurrences = 83) (number of all recurrences = 107)
Univariate Multivariate Univariate Multivariate
LR-χ2 LR-χ2a LR-χ2 LR-χ2a
(P value) (P value) (P value) (P value)
Nodal status (negative versus positive) 17.24 7.60 30.80 18.99
(<0.0001) (0.006) (<0.0001) (<0.0001)
Tumor size (≤2 versus >2 cm) 28.95 10.96 25.40 13.03
(<0.0001) (0.0009) (<0.0001) (0.0003)
Grade (well/moderate versus poor) 21.88 5.22 1.74 -
(<0.0001) (0.02) (0.2)
ER10 12.17 5.51 1.65 -
(0.004) (0.02) (0.2)
PgR10 18.81 6.46 1.45 -
(<0.0001) (0.01) (0.2)
Ki67 17.90 6.52 9.04 2.14
(<0.0001) (0.01) (0.003) (0.1)
HER2 (negative versus positive) 15.45 3.18 0.04 -
(<0.0001) (0.07) (0.8)
aFor addition to model containing all other factors that were significant in the univariate model. ATAC, Arimidex, Tamoxifen, Alone or in Combination; ER, estrogen
receptor; HER2, human epidermal growth factor; LR, likelihood ratio; PgR, progesterone receptor. Table was adapted from [9].
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cancer [16]. TP53 gene mutation is very frequently found
in breast cancers [17]. High expression of p53 in HR-
positive tumors has been associated with risk of both early
and late recurrence [18]. Furthermore, Bianchini and
colleagues [19] investigated a mitotic kinase score (average
expression of 12 kinases) and an estrogen-related score
(four genes) and observed that women who recurred late
(after 5 years) had highly proliferative and high estrogen-
sensitive tumors. In contrast, in the transATAC trial, in
which ER, PgR, Ki67, and HER2 as measured by immuno-
histochemistry were analyzed for their prognostic value
for late distant recurrence, no prognostic information for
late recurrence was observed for any of these four markers
(Table 1) [9]. It remains to be seen whether these various
genes can prospectively predict late (distant) recurrence
and be implemented in the clinical setting.
Molecular scores
Over the past decade, many molecular markers have
been developed for the prediction of recurrence risk.
Most of them are good prognostic markers during the
first 5 years after diagnosis (Table 2). All of these
markers have in common that they evaluate the patient’s
individual risk of recurrence (ROR) by combining expres-
sion profiles of a panel of cancer-related genes. However,
they need to be combined with traditional clinicopatholog-
ical factors to make use of all available information on
prognosis.
Currently, seven genomic assays are available for use in
early-stage breast cancer (Table 2). All of these give an
overall risk assessment of breast cancer recurrence and
provide prognostic information not contained in clinico-
pathological factors. None of these signatures was specific-
ally developed for predicting late (distant) recurrence;
nevertheless, some of them have been investigated in this
context, as summarized below.
Current genetic tests for the prediction
of recurrence
MammaPrint
The MammaPrint (Agendia, Irvine, CA, USA) is a 70
gene-based molecular score, which was developed in a
cohort of women who did not receive systemic therapy
and with no long-term clinical outcome data [20,21]. The
genes included in the MammaPrint are all related to the
regulation of cell cycle, invasion, metastasis, proliferation,
and angiogenesis and were retrospectively selected. This
multi-gene score classifies women into low-risk (good
prognosis) or high-risk (bad prognosis) groups according
to their 10-year distant recurrence risk of less than 10% or
more than 10%, respectively, but no continuous score is
available for MammaPrint. The signature was validated
in two studies in women with node-negative or node-
positive disease and showed that the test predicted breast
cancer recurrence accurately [20,21]. The predictive
value of this test is being evaluated in the MINDACT
(Microarray In Node-negative and 1-3 node-positive
Disease may Avoid Chemo Therapy) trial where women
are randomly assigned to chemotherapy plus endocrine
therapy or endocrine therapy alone if the results between
MammaPrint and Adjuvant Online! were discordant [22].
The MammaPrint has been evaluated in many patient
subgroups, but the prognostic information added by this
assay is confined to the first 5 years after diagnosis.
Genomic grade index
The Genomic Grade Index (Ipsogen, now known as
Qiagen Marseille, Marseille, France) is a 97 gene-based
Table 2 Summary of multi-gene/molecular scores for the prediction of recurrence
Score Abbreviation Details Reference
MammaPrint MammaPrint 70 gene-based expression profile using DNA microarray. Fresh frozen material is
used to perform analysis.
[20,21]
Genomic Grade Index GGI 97 gene-based assay using DNA micro array. Fresh frozen material is used to
perform the analysis.
[23,24]
Oncotype Dx Recurrence Score RS 21 gene-based expression profile score using qRT-PCR (16 cancer genes,
5 housekeeping genes). FFPE blocks used to extract RNA.
[25]
Immunohistochemical Score 4 IHC4 Includes information on estrogen receptor (ER), progesterone receptor (PgR),
Ki67, and HER2. Score developed on transATAC data. FFPE blocks used to
extract RNA to perform IHC for ER, PgR, Ki67, and HER2.
[31]
Prosina Risk of Recurrence Score ROR 50 gene-based expression profile score using qRT-PCR. FFPE blocks used to
extract RNA to perform analysis on nCounter system.
[34]
Breast Cancer Index BCI Multi-gene assay using qRT-PCR. Combination of two biomarkers HOXB13/IL17BR
(H/I) and molecular grade index (MGI). FFPE blocks used to extract RNA to perform
analysis.
[38,53]
EndoPredict EPclin 12 gene-based expression profile score using qRT-PCR (8 cancer genes,
4 housekeeping genes). FFPE blocks used to extract RNA to perform analysis.
[41]
ATAC, Arimidex, Tamoxifen, Alone or in Combination; FFPE, formalin-fixed paraffin-embedded; HER2, human epidermal growth factor; qRT-PCR, quantitative real-time
polymerase chain reaction.
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assay including mostly proliferation genes and was devel-
oped to refine the commonly used histological grade
assessment (low, intermediate, and high). The assay classi-
fies women into low- or high-grade groups and has been
shown to better define tumor grade, patient prognosis,
and breast cancer subtypes [23,24]. Again, this assay has
been validated in many different patient subgroups, and
the prediction of (distant) recurrence was limited to 5 years
after diagnosis.
Oncotype DX recurrence score
The 21 gene-based Oncotype Recurrence Score (Genomic
Health, Redwood City, CA, USA) is a well-established
multi-gene assay, which was developed to assess the risk
of recurrence in women with HR-positive, node-negative
breast cancer treated with tamoxifen [25]. The signature is
based on 16 breast cancer-specific genes and five reference
genes, including information on proliferation, estrogen,
invasion, HER2, and other factors [25]. A mathematical
algorithm was used to generate a continuous recurrence
score (RS), with a higher RS corresponding to an increased
risk of recurrence. The RS furthermore classifies women
into low-risk (less than 18), intermediate-risk (18 to 30),
and high-risk (more than 30) groups for recurrence. The
RS has been validated and evaluated in a number of clin-
ical trials and patient subgroups, and all results confirm
the prognostic performance of the RS score for (distant)
recurrence in the first 5 years after diagnosis [25-27].
The Oncotype RS has also been investigated in post-
menopausal women receiving aromatase inhibitors as
adjuvant treatment. In the transATAC trial [28], the RS
has been evaluated in 1,125 postmenopausal women
who were chemotherapy-free and who received either
tamoxifen or anastrozole alone for 5 years. In this pa-
tient group, the RS was shown to add significant prog-
nostic information for distant recurrence, independently
of clinicopathological factors and Adjuvant Online!. The
results furthermore confirmed that a combination of
molecular predictors, as found in the RS, and clinical
factors would provide a good prognostic tool for clini-
cians and oncologists [28].
The predictive value of the Oncotype RS has not been
evaluated in the transATAC trial, but other studies have
shown that women with a low RS will benefit little if at
all from additional chemotherapy [26,27,29,30]. Never-
theless, the RS analysis in the transATAC trial confirmed
indirectly that those with a very low RS, even with one
to three positive nodes, will not benefit from additional
chemotherapy.
The prognostic performance of the RS for late distant
recurrence was furthermore evaluated in the transATAC
trial [9] and compared with clinical factors and other
molecular scores. The Oncotype RS added significant
prognostic value in the first 5 years after breast cancer
diagnosis but failed to be substantially predictive of late
distant recurrence in the overall population in years 5 to
10 when adjusted for clinical parameters. The RS was
more prognostic for late metastasis in women with
HER2-negative disease and added little prognostic value
for those with node-positive disease [9]. The RS was
least prognostic for late distant recurrence when com-
pared with other multi-gene scores, such as the PAM50
ROR score or the immunohistochemistry 4 (IHC4) score
[31] (ER, PgR, Ki67, and HER2). The results of this
analysis showed that the RS is not a strong candidate for
the prediction of late distant recurrence.
Prosigna PAM50 risk of recurrence
The PAM50 ROR (NanoString Technologies, Seattle,
WA, USA) score is based on a 50-gene test, which was
developed to identify intrinsic breast cancer subtypes
[32,33]. The ROR is derived from an expression profile
of the 50 genes and includes information on tumor size
as well. The ROR score has been validated in women
with node-negative or node-positive disease [32,33] and
has been shown to classify women into low- or high-risk
groups and added prognostic information beyond that of
clinical or IHC4 factors.
In the transATAC trial, the PAM50 has been evaluated
for the ability to add prognostic information for distant
recurrence beyond that of clinical factors [34]. Further-
more, the prediction of distant recurrence in years 0 to
10 was compared with the Oncotype RS and IHC4 as
well. The results showed that the ROR added significant
prognostic information beyond that of clinical parame-
ters in all patients and furthermore in all subgroups as
well. In addition, it was shown that the ROR was more
predictive of distant recurrence overall than the Onco-
type RS and categorized more patients into the high-risk
group and fewer into the intermediate-risk group than
the RS, indicating better discrimination of risk groups.
The ROR score was also evaluated in the ABCSG-8
(Austrian Breast and Colorectal Cancer Study Group 8)
trial, in which postmenopausal women with early breast
cancer were randomly assigned to receive tamoxifen or
anastrozole for 5 years [35]. In this large analysis, the
ROR score added significant prognostic value beyond
that of clinical parameters for distant recurrence in the
overall population and all subgroups. It also confirmed
the better discrimination between low- and high-risk
groups in all subgroups.
The ROR score was further investigated for the predic-
tion of late distant recurrence in the transATAC trial [9].
In this context, the ROR score was the most prognostic
overall and in all patient subgroups, when compared
with the Onctoype RS and IHC4, and reclassified more
women into the low- or high-risk group than the other
two tests. This was the first analysis to show that the
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ROR score, though developed to predict overall recur-
rence, added significant prognostic information for late
distant recurrence. In a combined analysis of the trans-
ATAC and ABCSG-8 trials, the ROR score was inves-
tigated for the prediction of specifically late distant
recurrence [36]. Two thousand one hundred and thirty-
seven postmenopausal women who did not have a recur-
rence in the first 5 years after diagnosis were included in
the analysis. In both the univariate and bivariate analyses
(adjusted for clinical parameters), the ROR score added
significant prognostic information for late distant recur-
rence in all patients and was more predictive in node-
negative and node-negative/HER2-negative patients than
clinical factors alone [36]. The results of this analysis
indicated that the ROR score is able to identify women
who are at sufficiently low risk of late distant recurrence,
even if they have node-positive disease, and who might
be spared additional endocrine therapy and therefore
overtreatment.
Breast cancer index
The Breast Cancer Index (BCI) (bioTheranostics, San
Diego, CA, USA) is a gene expression module based on
two components - the HOXB13/IL17BR (H/I) and the
molecular grade index (MGI), which is a proliferation
module. The continuous BCI score with a cubic compo-
nent has been developed in tamoxifen-treated women
with lymph node-negative disease and has been shown
to be a good predictor for distant recurrence in this
cohort [37]. A second risk model was developed by com-
bining H/I and MGI into a linear, continuous risk score
[38] and this model provided better significant prognos-
tic information for distant recurrence in node-negative
patients. Furthermore, the linear BCI stratified the
majority of women as low risk for distant recurrence in
years 0 to 5 and also in years 5 to 10 after diagnosis.
The BCI was further evaluated in the transATAC
cohort in which both the cubic BCI and the linear BCI
were investigated for the prediction of distant recurrence
in the early and late follow-up period [39]. The results of
this analysis showed that only the linear BCI as a con-
tinuous score was an independent strong predictor for
distant recurrence in women with node-negative or
HER2-negative/node-negative disease. As a categorical
score, the linear BCI compared low-, intermediate-, and
high-risk groups, and significant differences in distant
recurrence rates at 5 years of follow-up were found
for the high-risk group when compared with the low/
intermediate-risk group (1.3% versus 5.6% versus 18.1%;
P < 0.001). Conversely, in years 5 to 10 after diagnosis, the
low-risk group had a recurrence rate of 3.5%, which was
significantly lower when compared with the intermediate-
risk (13.4%) and high-risk (13.3%) group (P = 0.001). To
further evaluate whether both components of the BCI
score predict for late distant recurrence, an exploratory
analysis was performed to investigate the prognostic
performance of each component separately. The results
showed that, although both components added prognostic
value in the first 5 years after diagnosis when adjusted for
clinical parameters, only H/I also significantly predicted
for late recurrence [39]. The finding that MGI is not prog-
nostic for late distant recurrence is consistent with other
results [9] in which proliferation-related factors, such as
Ki67 or clinical tumor grade, are not prognostic for late
distant recurrence. Overall, the BCI identifies women with
node-negative disease at increased risk of late distant
recurrence and might be used in the clinical setting to
identify women who might benefit from further endocrine
therapy. However, this signature has not been evaluated in
women with node-positive disease.
EndoPredict
The EndoPredict (EP) (Sividon, Cologne, Germany) has
been developed for women with HR-positive/HER2-
negative disease and includes information of eight cancer-
related and three normalization genes [40]. The signature
has been validated in a cohort of women from two large
clinical trials (ABCSG-6/8), which were treated with adju-
vant endocrine therapy only. Apart from the EP score, a
second score, EPclin, has been developed, which combines
the EP score with clinical information, such as nodal status
and tumor size. Both signatures are available as con-
tinuous scores or as low-risk and high risk groups as
defined by pre-specified cutoff points. In both valid-
ation cohorts, the EP was an independent predictor of
distant recurrence beyond that of clinical variables. Fur-
thermore, the EPclin provided additional prognostic in-
formation beyond that of clinicopathological parameters
alone in women with HER2-negative breast cancer. In
the same two cohorts, the EP and EPclin were specific-
ally investigated for the prediction of late distant recur-
rence [41]. The results showed that both signatures are
clearly associated with the prediction of late metastasis.
The EPclin furthermore identified a subgroup of pa-
tients who have a very good prognosis after 5 years of
endocrine therapy.
Novel predictors
None of the multi-gene tests discussed above was specif-
ically developed for the prediction of late recurrence,
and there is great interest in new biomarkers for the pre-
diction of these events. The ultimate goal of a new bio-
marker is that it specifically predicts for either early or
late recurrence. Cheng and colleagues [42] identified a
51-gene signature from primary breast cancer tumors,
which are particularly associated with late recurrence.
Although this gene signature has not been validated yet,
it suggests that novel biomarkers might help to identify
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women who might be at risk of late recurrence and
therefore candidates for extended therapy.
A new area of great interest is the identification of
circulating tumor cells (CTCs) in peripheral blood of
patients with breast cancer (from either primary tumor
or metastasis). CTCs have been linked to worse prog-
nosis and early relapse in breast cancer and can be
used for the identification of response to treatment
[43]. Many studies have shown that CTCs in early
breast cancer predict recurrence within the first 5 years
after diagnosis [44-47]. An overview of all studies inves-
tigating CTCs for detection of metastatic breast cancer
was recently published [48] (Table 3). CTCs thus far
have been investigated mostly in the metastatic setting,
and further research is needed for the early breast can-
cer setting.
In addition, the detection of one or more CTCs in
the first 5 years after diagnosis has been associated with
late relapse in early breast cancer [49]. A potential ad-
vantage of CTCs is that their presence can be measured
at several time points during disease from blood sam-
ples (‘liquid biopsies’) and thus give information on dis-
ease progression. However, it is still not clear what the
best detection method for CTCs is, as these cells occur
at a very low yield. Another research area that needs to
be addressed is the correct time point of measuring
CTCs for late relapse. Although it has been become
clear that CTCs are a powerful marker for the predic-
tion of early metastatic disease, not many studies have
specifically addressed the use of CTCs for the identifi-
cation of late relapse and this area of research needs
further investigation.
Conclusions
It is important to accurately identify women at high risk
of late (distant) recurrence as some of them may be
spared extended endocrine therapy whereas others may
benefit from further treatment. Risk of distant recur-
rence and timing vary among patients with breast can-
cer. Clinicopathological parameters, specifically nodal
status and tumor size, are well-established predictors for
late recurrence in postmenopausal women with HR-
positive breast cancer. However, it has become evident
that molecular signatures improve the prediction of late
relapse and can identify women who are at sufficiently
low risk, even with node-positive disease, who do not
warrant extended endocrine therapy. The ROR score,
the BCI, and the EP score all have been shown to add
significant prognostic information for late (distant) recur-
rence in postmenopausal women who are chemotherapy-
free and these results indicate that these signatures may be
helpful in the clinical setting.
However, the question of which molecular test is best
for each individual patient needs further research. Al-
though all of the signatures predict early and some of
them late recurrence in a variety of patients, it has be-
come apparent that tumor biology is not all that matters.
Non-clinical baseline factors, such as age or body mass
index, may influence the prognostication of these signa-
tures [50] and furthermore may help to identify specific
women who will benefit most from these tests.
The difficulty that all discussed molecular signatures
have in common is that the information is derived from
the primary tumor, assuming that driving forces for late
recurrences are in these primary tumors. This might be
Table 3 Summary of ongoing clinical trials with circulating tumor cells in metastatic breast cancer
Trial Study design Reference
STIC CTC METABREAST 1,000 hormone receptor-positive, metastatic breast cancer patients randomly assigned to either
standard arm or CTC-driven arm, which dictates whether hormone therapy (5 CTCs <7.5 mL)
or to chemotherapy (5 CTCs ≥7.5 mL) is administered. Trial aims to show non-inferiority of the
CTC arm versus standard arm for progression-free survival.
[54]
SWOG 0500 Screening patients with metastatic disease and more than 5 CTCs (n = 610) and randomization
between continuation of first-line therapy (CTC response, <5 CTC/7.5 mL) and switch to another
chemotherapy regime (no CTC response, ≥5 CTCs/7.5 mL) (n = 120). Primary endpoint is
improvement in overall survival in the CTC-driven arm.
[55]
CirCe01 304 women with metastatic disease starting with third-line chemotherapy will be randomly
assigned between a CTC-driven arm and standard care arm. Patients in the CTC-driven arm
change chemotherapy regimens according to their CTC counts during treatment. Primary
endpoint is overall survival.
[56]
Treat CTC Patients with HER2-negative breast cancer having completed chemotherapy and primary
surgery and with at least 1 CTC/15 mL will be randomly assigned to an observation arm or
to receive trastuzamab. Primary endpoint is detection rate of CTCs after 18 weeks between
the two arms.
NCT01548677
DETECT III Around 300 patients with metastatic and HER2-negative disease with detectable at least one
HER2-positive CTC/7.5 mL will be randomly assigned to receive standard care (endocrine
or chemotherapy or both) versus standard care plus lapatinib. Primary endpoint is
progression-free survival.
NCT01619111
CTC, circulating tumor cell; HER2, human epidermal growth factor.
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true for early relapses but not necessarily for late recur-
rence. Dormant micrometastasis cells might survive for
a long time in distant organs and undergo genetic
changes, which might drive the recurrence but not
be present in the primary tumor [51]. CTCs (micro-
metastasis) may stay dormant in distant organs for many
years, and genetic changes of these cells may arise and re-
flect differences in these cells that are distinctively diverse
from those of the primary tumor [52]. Therefore, it re-
mains a challenge to accurately classify primary tumors
for the prediction of late recurrences.
Many molecular signatures have been evaluated and
validated in large clinical trials, and most of them are
officially approved for use in the clinic. None of the dis-
cussed signatures has been developed particularly for the
prediction of late (distant) recurrence. Nevertheless, the
results clearly show that some of them have great poten-
tial for the identification of women who are at high risk
of developing a late recurrence, particularly those with
node-negative disease. With the help of these signatures,
tailored therapies and specific patient treatments can be
optimized for late (distant) recurrence.
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